Halogenierte Benzimidazole und Benzotriazole als Hemmstoffe der NTPase/Helikase von Hepatitis C und verwandten Viren
,
Halogenated banzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses
Staats- und Universitätsbibliothek Hamburg Carl von Ossietzky
Erscheinungsjahr:
2008
Medientyp:
Text
Schlagworte:
610 Medizin, Gesundheit
44.43 Medizinische Mikrobiologie
Flaviviren
Nucleosidanaloga
Helicase
Benzimidazol
Hepatitis C
ddc:610
Flaviviren
Nucleosidanaloga
Helicase
Benzimidazol
Hepatitis C
Beschreibung:
A search has been initiated for lead inhibitors of the non-structural protein 3 (NS3)-associated NTPase/helicase activities of hepatitis C virus, the related West Nile virus, Japanese encephalitis virus and the human mitochondrial Suv3 enzyme. Random screening of a broad range of unrelated low-molecular mass compounds, employing both RNA and DNA substrates, revealed that 4,5,6,7-tetrabromobenzotriazole (TBBT) hitherto known as a potent highly selective inhibitor of protein kinase 2, is a good inhibitor of the helicase, but not NTPase, activity of hepatitis C virus NTPase/helicase. The IC50 is approximately 20 µM with a DNA substrate,but only 60 µM with an RNA substrate. Several related analogues of TBBT were enzyme and/or substrate-specific inhibitors. For example, 5,6-dichloro-1-(â-D-ribofuranosyl)benzotriazole (DRBT) was a good, and selective, inhibitor of the West Nile virus enzyme with an RNA substrate (IC50 ~ 0.3 µM),but much weaker with a DNA substrate (IC50 ~ 3 µM). Preincubation of the enzymes, but not substrates, with DRBT enhanced inhibitory potency, e.g. the IC50 vs the hepatitis C virus helicase activity was reduced from 1.5 to 0.1 µM. No effect of preincubation was noted with TBBT, suggesting a different mode of interaction with the enzyme. The tetrachloro congener of TBBT, 4,5,6,7,-tetrachlorobenzotriazole (TCBT; a much weaker inhibitor of casein kinase 2) is also a much weaker inhibitor than TBBT of all four helicases. Kinetic studies, supplemented by comparison of ATP-binding sites, indicated that, unlike the case with casein kinase 2, the mode of action of the inhibitors vs the helicases is not by interaction with the catalytic ATP-binding site, but rather by occupation of an allosteric nucleoside/nucleotide binding site. The halogeno benzimidazoles and benzotriazoles included in this study are excellent lead compounds for the development of more potent inhibitors of hepatitis C virus and other viral NTPase/helicases.